Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Glycopyrrolate inhalation - Novartis

Drug Profile

Glycopyrrolate inhalation - Novartis

Alternative Names: AD-237; Enurev Breezhaler; Inhaled glycopyrrolate; Inhaled glycopyrronium bromide; NVA-237; Seebri Breezhaler; Seebri Inhalation Capsules; Seebri Neohaler; SeebriBreezhaler; Tovanor Breezhaler

Latest Information Update: 15 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arakis Ltd; Vectura
  • Developer Novartis; Sunovion Pharmaceuticals
  • Class Antiasthmatics; Antispasmodics; Antiulcers; Pyrrolidines; Quaternary ammonium compounds; Skin disorder therapies; Small molecules
  • Mechanism of Action Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease
  • Phase II Asthma

Most Recent Events

  • 24 Jun 2019 Glycopyrrolate inhalation licensed to Glenmark in Brazil
  • 18 May 2018 Efficacy data from the phase III GEM 2 trial in Chronic obstructive pulmonary disease presented at the 114th International Conference of the American Thoracic Society
  • 18 May 2018 Pooled efficacy data from the phase III GEM 1 and GEM 2 trials in Chronic obstructive pulmonary disease presented at the 114th International Conference of the American Thoracic Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top